Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Opioid Dependence
Interventions
DRUG

Probuphine (buprenorphine implant)

Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).

Trial Locations (15)

19104

University of Pennsylvania, Treatment Research Center, Philadelphia

27705

Duke Addictions Program, Durham

32256

Amit Vijapura, MD, Jacksonville

33161

Scientific Clinical Research, Inc., North Miami

63128

Psych Care Consultants Research, St Louis

73118

Pahl Pharmaceutical Research, LLC, Oklahoma City

91950

Synergy Clinical Research Center, National City

Unknown

David Geffen School of Medicine at UCLA, Los Angeles

Fidelity Clinical Research, Inc., Lauderhill

Behavioral Biology Research Unit, Johns Hopkins Bayview Campus, Baltimore

Dual Diagnosis Unit, SSTAR: Stanley Street Treatment and Resources, Inc., Fall River

Wayne State Univ. School of Medicine, Dept of Psychiatry & Behavioral Neuroscience, Detroit

New York VA Medical Center, NYU School of Medicine, New York

Puget Sound Health CareSystem, Seattle

98201-1067

Providence Behavioral Health Services, Everett

Sponsors
All Listed Sponsors
lead

Titan Pharmaceuticals

INDUSTRY

NCT00630201 - Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence | Biotech Hunter | Biotech Hunter